Skip to main content
Mankind Pharma Limited logo

Mankind Pharma Limited — Investor Relations & Filings

Ticker · MANKIND ISIN · INE634S01028 LEI · 33580067G8AZ7S8NYA02 BSE.NS Manufacturing
Open in API
Filings indexed 397 across all filing types
Latest filing 2026-02-03 Regulatory Filings
Country IN India
Listing BSE.NS MANKIND

About Mankind Pharma Limited

https://www.mankindpharma.com/

Mankind Pharma Limited focuses on the development, manufacturing, and marketing of a broad spectrum of pharmaceutical formulations and consumer healthcare products. The company’s portfolio spans various therapeutic areas, including anti-infectives, cardiovascular, gastrointestinal, dermatology, and respiratory health. It maintains a significant presence in the over-the-counter segment with brands such as Manforce, Prega News, and Gas-O-Fast. The organization operates a robust research and development infrastructure dedicated to creating affordable and accessible medicinal solutions. Its operational model leverages an extensive distribution network to ensure product availability across diverse geographic regions, prioritizing high-quality healthcare delivery and patient-centric innovation.

Recent filings

Filing Released Lang Actions
Investor Presentation
Regulatory Filings
2026-02-03 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release dated February 3, 2026, announcing the financial results of Mankind Pharma for the third quarter and nine months ended December 31, 2025. It includes detailed financial performance data such as revenue, EBITDA, PAT, segmental revenue breakup, and growth percentages. The document also mentions an upcoming earnings conference call. The content is typical of an Earnings Release, which is an initial announcement of quarterly financial results with key highlights. The document is about 12,402 characters long, which is consistent with a detailed earnings release rather than a full interim or annual report. There is no indication that this is a full interim report (IR) or annual report (10-K), nor is it a transcript of the earnings call (CT). It is not a regulatory filing or announcement of a report publication. Therefore, the most appropriate classification is Earnings Release (ER).
2026-02-03 English
Outcome of Board Meeting
Regulatory Filings
2026-02-03 English
Credit Rating
Capital/Financing Update Classification · 95% confidence The document is a formal disclosure addressed to stock exchanges regarding the withdrawal and status of credit ratings for certain financial instruments of the company. It references SEBI Listing Obligations and Disclosure Requirements Regulations, which govern such disclosures. The content focuses on credit rating updates, not on financial results, management changes, or detailed financial reports. The document length is short (1771 characters) and it serves as an announcement of credit rating status changes. This fits the category of a Capital/Financing Update (CAP), as it relates to the company's financing instruments and their credit ratings.
2026-01-16 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 80% confidence The document is an announcement dated January 16, 2026, informing about an upcoming investor conference call scheduled for February 3, 2026, to discuss Q3 & 9M FY26 business performance and results. It includes details such as dial-in numbers, management participants, and contact information. The document does not contain any financial data or results itself, but rather serves as an invitation and notification of the call. According to the classification rules, a full transcript of the call would be classified as a Call Transcript (CT), but this document is only an announcement of the call, not the transcript or the earnings release itself. Since it is an announcement of an earnings call, the most appropriate classification is Call Transcript (CT) as it relates directly to the call content, but given it is only an invitation, it is best classified as a Call Transcript (CT) with moderate confidence because it is not the transcript but the call invite. However, since the category CT is specifically for full transcripts, and this is only an invitation, the best fit is Regulatory Filings (RNS) as a general announcement related to the call. But the document is specifically an investor conference call invitation for earnings, which is commonly classified as Call Transcript (CT) or sometimes as Investor Presentation (IP). Since it is not a presentation but a call invite, CT is the closest. Confidence is moderate at 0.8 due to the document being an invite rather than a transcript.
2026-01-16 English
Board Meeting — Board Meeting Intimation
Regulatory Filings
2026-01-09 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.